Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 11

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 11
---
 engage in commercial
marketing activities or sales efforts and we have no experience in marketing our products. If we are unable to establish marketing and
sales capabilities or enter into agreements with third parties to market and sell our Alpha DaRT technology, if approved or certified
for commercial sale, we may not be able to generate product revenue.

While we have taken steps
to build our marketing team, we do not currently engage in commercial marketing activities or sales efforts and we have no experience
in marketing our products. We intend to further develop an in-house marketing organization and sales force, which will require significant
capital expenditures, management resources and time. We will have to compete with other pharmaceutical, medical device and biotechnology
companies to recruit, hire, train and retain marketing and sales personnel.

If we are unable to establish
internal sales and marketing capabilities to our satisfaction, we will pursue collaborative arrangements regarding the sales and marketing
of our products, if licensed, as we have done in Canada and Israel, and are currently examining such potential arrangements in certain
Asian markets. However, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if
we are able to do so, that they will have effective sales forces. Any revenue we receive will depend upon the efforts of such third parties,
which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue
from product sales may be lower than if we had commercialized our Alpha DaRT technology ourselves. We also face competition in our search
for third parties to assist us with the sales and marketing efforts of our Alpha DaRT technology.

There can be no assurance
that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators
to commercialize any product in the United States or overseas for which we are able to obtain marketing authorization or certification.

We may expend our resources to pursue a
particular indication and forgo the opportunity to capitalize on Alpha DaRT technology in indications that may ultimately be more profitable
or for which there is a greater likelihood of success.

We have limited financial
and personnel resources and as such, we may determine to place significant focus on the development of our Alpha DaRT technology in certain
indications, and as such, we may forgo or delay pursuit of opportunities with other future products or product candidates or other indications
that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize